Ondine to Spotlight Long-Term Infection Control Gains from Steriwave at Global Congress

An update from Ondine Biomedical, Inc. ( (GB:OBI) ) is now available.

Ondine Biomedical Inc. will present two new research abstracts at the 2026 World Congress on Infectious Diseases in Barcelona, showcasing long-term clinical and economic data on its Steriwave light-activated antimicrobial technology in surgical settings. The eight-year longitudinal results indicate improved outcomes versus standard antibiotic regimens, highlighting sustained reductions in surgical site infections and the absence of resistance development.

One abstract reports a 66% reduction in surgical site infections in spine surgery using nasal photodisinfection over eight years, demonstrating durable efficacy and cost savings in complex operations. The second examines how under-reporting and mispricing of cardiac surgical infections can mask their true clinical and financial burden, arguing that more accurate data could unlock hospital capacity and support reforms to combat antimicrobial resistance and improve patient safety.

The selection of Ondine’s work for a global infectious disease forum underscores growing interest in non-antibiotic technologies as healthcare systems confront rising antimicrobial resistance and hospital-acquired infections. By positioning Steriwave as an immediate, resistance-avoiding alternative to topical antibiotics, Ondine strengthens its profile among clinicians and policymakers seeking scalable infection-prevention solutions across high-risk surgical environments.

Spark’s Take on OBI Stock

According to Spark, TipRanks’ AI Analyst, OBI is a Underperform.

Ondine Biomedical, Inc. receives a low overall score due to significant financial performance challenges, bearish technical indicators, and unattractive valuation metrics. The company’s strong revenue growth is overshadowed by its inability to achieve profitability and positive cash flow, while technical analysis suggests continued negative momentum.

To see Spark’s full report on OBI stock, click here.

More about Ondine Biomedical, Inc.

Ondine Biomedical Inc. is a Canadian life sciences company specialising in light-activated antimicrobial therapies, known as photodisinfection, to prevent and treat infections, including those caused by multidrug-resistant organisms. Its lead product, the Steriwave nasal photodisinfection system, is approved for nasal decolonisation in multiple countries, carries a CE mark in Europe, holds priority designations from the U.S. FDA, and anchors a broader pipeline targeting conditions such as chronic sinusitis, ventilator-associated pneumonia and burns.

Average Trading Volume: 264,170

Technical Sentiment Signal: Hold

Current Market Cap: £59.61M

See more data about OBI stock on TipRanks’ Stock Analysis page.